Posted on

Biomind begins DMT trial

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Biomind Labs (BMND) dosed the first subject in a Phase I trial /IIa clinical trial on DMT for treatment-resistant depression.

Over the next 4 months, 30 healthy patients who have never done psychedelics will receive 2 doses of inhalable DMT. Researchers will assess the safety of the drug, as well as behavioral and brain effects before continuing with Phase II.

Can you imagine trying DMT as your first psychedelic?

PDF of article

Posted on

Magic mushroom dispensaries in Canada’s capital 🍁

This Ottawa store is selling magic mushrooms to protest ‘unjust’ laws

The Golden Teacher is a “grey-area research facility” and mushroom dispensary in Ottawa that wants to make bad trips obsolete.

Owner Jordan Armstrong aims to understand how magic mushrooms affect individuals differently by surveying each customer. The goal is gather data to regulate the fungi properly.

Ottawa’s second mushroom dispensary, Shroomyz, will be opening on May 1st!

Shroomyz is located on Preston Street and The Golden Teacher is on the corner of Rideau and Dalhousie Streets.
Posted on

Psychedelic startup makes a deal with Big Pharma

Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets

Terran Biosciences, a private psychedelic startup, announced a licensing deal with the French Big Pharma company Sanofi (SNY). Terran will license two of Sanofi’s pipeline assets that target central nervous system (CNS) disorders. The assets have generated more than 100 clinical studies involving 15,000 subjects on a variety of CNS disorders.

PDF of article

Posted on

Attention psychedelic researchers 🚨

Here’s two new opportunities to get your research funded:

  1. COMPASS Pathways (CMPS) is sponsoring three One Mind Rising Star Awards – a $300,000 research grant for mental health researchers.
  2. The Canadian Institutes of Health Research (CIHR) is launching a $3M grant program to support psilocybin clinical trials on:
  • Substance use disorders
  • Major depressive disorder or treatment resistant depression
  • End-of-life distress in late-stage cancer patients

PDF of article 1

PDF of article 2

Posted on

Microdosing for stroke recovery

Psychedelic Pharmaceutical Startup Ninnion Announces Patent Filings and Development of NIN-S119 for Ischemic Stroke

Ninnion Therapeutics, a private Texas-based company, hopes microdosing will help patients recover from strokes.

Ischemic strokes block blood flow to the brain, causing brain cells to die. 

Microdosing in combination with occupational therapy may be able to strengthen the remaining brain cells to restore lost functions.

The company recently filed a patent application for the treatment. Since there are no approved drugs for stroke recovery, the formulation may qualify for a Breakthrough Therapy designation, which would speed up the development timeline. 

PDF of article

Posted on

Help legalize medical psilocybin

Help TheraPsil-Supported Patients and Clinicians Fight for Legal Psilocybin

By denying Canadians access to psilocybin, the government is infringing on patients’ rights. According to TheraPsil, the decision to use psilocybin medically should be made between doctor and patient with no requirement for government approval (just like medical cannabis).

If you believe that access to psilocybin for medical purposes is a right, please help TheraPsil prove this in court by donating to their fundraiser.

PDF of article

Posted on

“I felt joy like I’ve never experienced”

‘I felt more joy than I thought possible’

Steve struggled with depression for 30 years. Traditional antidepressants numbed both his highs and lows, leaving him feeling like a “functional zombie”.

Things finally changed when he volunteered for a psilocybin trial at Imperial College London.  

“With the first dose, I felt joy like I’ve never experienced – and more like myself than I’ve ever felt… It took from not knowing myself at all to having a sense of what my place was in the greater scheme of things,” he said.

The second dose was much more challenging, but “therapeutically more useful,” as it forced him to deal with suppressed emotions.

“The drug gives us part of a healing process. It exposes you to different possibilities – another way of being,” Steve explains.

PDF of article

Posted on

A cure for acid flashbacks

Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD

Ehave Inc. (EHVVF) and University of Melbourne are launching a series of studies to better understand a condition called hallucinogen-persisting perception disorder (HPPD). Basically, HPPD is when someone continues to experience visual hallucinations after a trip.

Researchers will conduct genetic analysis and visual processing tests to see if individuals can be genetically predisposed to HPPD. 

Ehave’s goal is to find a cure for the disorder and become an “industry leader in preventing negative side effects during treatment for mental health issues.”

PDF of article

Posted on

First household name enters psychedelic sector

Irwin Naturals strikes deal to acquire chain of ketamine treatment clinics in Florida and Mexico

Irwin Naturals (IWIN), a major supplement company established in 1994, is acquiring a chain of ketamine clinics in Florida and Mexico, becoming the “world’s first household name to enter the psychedelic mental health treatment sector.” This acquisition is part of a plan to create the world’s largest chain of psychedelic clinics.

PDF of article